# Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

> **NCT00088595** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 45 (actual)

## Conditions studied

- Carcinoid Tumors

## Interventions

- **DRUG:** Pasireotide (SOM230)

## Key facts

- **NCT ID:** NCT00088595
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2012-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088595, "Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00088595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*